Author + information
- Lamin King,
- Antionette de Waha,
- Giuio Stefanini,
- Robert A. Byrne,
- Bernhard Meier,
- Adnan Kastrati and
- Stephan Windecker
Patients with diabetes have higher rates of restenosis and stent thrombosis after percutaneous coronary intervention. By improving biocompatibility and vascular healing, biodegradable polymer drug–eluting stents (BP–DES) may potentially improve long–term outcomes in patients with diabetes.
We pooled individual patient–level data from 3 randomized clinical trials (LEADERS, ISAR TEST 3 and ISAR TEST 4) comparing BP–DES with durable polymer sirolimus–eluting stents (SES). Clinical outcomes were assessed to 4 years. The primary endpoint was a composite of cardiac death, myocardial infarction and target–lesion revascularization. Secondary endpoints were definite or probable stent thrombosis and target lesion revascularization.
Of 1094 patients with diabetes, 657 received biodegradable polymer DES and 437 durable polymer DES. Incidence of the primary endpoint at 4 years was similar in BP–DES vs. SES (25.0% vs. 26.6%; HR=0.95; P=0.68). Target lesion revascularization was also similar (15.5% vs. 17.4%; HR=0.89: P=0.46). Definite or probable stent thrombosis occurred less frequently with BP–DES (2.8% vs. 6.1%; HR 0.50; P=0.04) driven by significantly lower stent thrombosis rates with BP–DES between 1 and 4 years (0.4% vs. 2.7%; HR=0.15 P=0.02)
Biodegradable polymer DES demonstrate similar overall clinical outcomes to durable polymer SES during 4 year follow up in patients with diabetes. Rates of stent thrombosis were significantly lower with BP–DES.
Moderated Poster Contributions
Poster Sessions, Expo North
Saturday, March 09, 2013, 10:00 a.m.–10:45 a.m.
Session Title: Coronary Stents
Abstract Category: 47. TCT@ACC–i2: Coronary Intervention, Devices
Presentation Number: 2101M–218
- 2013 American College of Cardiology Foundation